International Journal of Advances in Science, Engineering and Technology(IJASEAT)
.
Follow Us On :
current issues
Volume-12,Issue-1  ( Jan, 2024 )
Past issues
  1. Volume-12,Issue-1  ( Jan, 2024 )
  2. Volume-11,Issue-4  ( Oct, 2023 )
  3. Volume-11,Issue-3  ( Jul, 2023 )
  4. Volume-11,Issue-2  ( Apr, 2023 )
  5. Volume-11,Issue-1  ( Jan, 2023 )
  6. Volume-10,Issue-4  ( Oct, 2022 )
  7. Volume-10,Issue-3  ( Jul, 2022 )
  8. Volume-10,Issue-2  ( Apr, 2022 )
  9. Volume-10,Issue-1  ( Jan, 2022 )
  10. Volume-9,Issue-4  ( Oct, 2021 )

Statistics report
Apr
Submitted Papers : 80
Accepted Papers : 10
Rejected Papers : 70
Acc. Perc : 12%
  Journal Paper


Paper Title :
L.Acidophillus and Bifidobacterium SPP Contribute in the Treatment of Chronic Hepatitis C Patients

Author :Nanis G.Allam, Mohamed L.Salem, Hassan Elbatae, Maii Moustafa Nabieh

Article Citation :Nanis G.Allam ,Mohamed L.Salem ,Hassan Elbatae ,Maii Moustafa Nabieh , (2017 ) " L.Acidophillus and Bifidobacterium SPP Contribute in the Treatment of Chronic Hepatitis C Patients " , International Journal of Advances in Science, Engineering and Technology(IJASEAT) , pp. 44-51, Volume-5, Issue-2, Spl. Iss-1

Abstract : Hepatitis C virus is a major leading cause of Liver pathogenesis. Probiotics showed a natural therapeutic activity against liver disorders. The antiviral and the antibacterial responses to L. acidophilus and Bifidobacteria spp in patients with chronic hepatitis C virus is a recommended study. Patients with chronic hepatitis C were treated with probiotics capsule that contains L. acidophilus and Bifidobacterium spp. They administered one capsule per day for a month before HCV treatment, blood and urine samples were collected before and after the given treatment and they were processed for a quantitative estimation of HCV by PCR, identification of bacteria by VITEK2 system and 16S r RNA gene sequencing assay, moreover, the estimation of antibacterial activity of probiotics, as well as counts of leukocytes, CD3 + T cells and CD56 + natural killer cells. Administration of Probiotics capsule enhanced the treatment response rate to HCV treatments as IFN-α and ribavirin by 25%. It had antibacterial activity against five species of the most common bacterial infections also It increased CD3 + cells counts and CD56 + natural killer cells in chronic HCV patients. Administration of probiotics as a capsule before HCV treatment can act as a supportive supplement with antiviral and antibacterial activities. Index Terms - CD3 + ; CD56 + ; Hepatitis C virus; Lactobacillus acidophilus; Bifidobacterium bifidum.

Type : Research paper

Published : Volume-5, Issue-2, Spl. Iss-1


DOIONLINE NO - IJASEAT-IRAJ-DOIONLINE-8006   View Here

Copyright: © Institute of Research and Journals

| PDF |
Viewed - 31
| Published on 2017-07-08
   
   
IRAJ Other Journals
IJASEAT updates
Volume-11,Issue-4 (Oct,2023)
The Conference World

JOURNAL SUPPORTED BY